Snapshot from Sep 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Business acquisition

RPG Active Pharma acquires Raghava API business

Analysis based on 10 articles · First reported Sep 03, 2026 · Last updated Sep 03, 2026

Sentiment
20
Attention
2
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The acquisition strengthens Tiziana Life Sciences' API business, potentially enhancing its market position and growth prospects in the growing API market. The stock rose over 1% on the announcement, reflecting positive investor sentiment, while the deal is expected to contribute to revenue growth once integrated.

Pharmaceuticals Active Pharmaceutical Ingredients

Tiziana Life Sciences, through its wholly-owned subsidiary RPG Active Pharma, has entered into a Business Transfer Agreement to acquire the API and intermediates business of Raghava Life Sciences on a going-concern basis via a slump sale for a consideration of up to Rs 135 crore. The acquisition adds a WHO-GMP and EU-GMP approved manufacturing facility near India — Hyderabad with approximately 300 KL installed capacity, a portfolio of 29 API molecules (22 commercialized and 7 under development) across therapeutic areas including diabetes, cardiovascular, and CNS. This is RPG Active Pharma's second acquisition in two months, following its earlier agreement to acquire Actis Generics, as part of a buy-and-build strategy to create an integrated, scaled API organization. The transaction is subject to customary closing conditions and regulatory approvals, and will be funded through a recent equity raise backed by InvAscent. Tiziana Life Sciences' shares rose following the announcement.

100 RPG Active Pharma acquired API business Raghava Life Sciences
60 RPG Active Pharma raised equity InvAscent
stock
Parent company executing its API consolidation strategy through subsidiary; stock rose on news.
Importance 100.0 Sentiment 20.0
priv
Acquiring entity; expands manufacturing base, product portfolio, and regulatory capabilities.
Importance 100.0 Sentiment 20.0
priv
Selling its API business; gains Rs 135 crore and exits API operations.
Importance 90.0 Sentiment 10.0
priv
Previously acquired by RPG Active Pharma; complements this deal with intermediates strength.
Importance 40.0 Sentiment 10.0
cnt
Country where the transaction occurs; aligns with API self-sufficiency push.
Importance 30.0 Sentiment 10.0
priv
Investor backing RPG Active Pharma's equity raise that funds the acquisition.
Importance 30.0 Sentiment 10.0
per
MD of Tiziana Life Sciences; articulated strategic rationale for the acquisition.
Importance 30.0 Sentiment 10.0
per
MD of Raghava Life Sciences; commented on the sale.
Importance 20.0 Sentiment 5.0
loc
Location of the acquired manufacturing facility.
Importance 20.0 Sentiment 5.0
priv
Legal advisor to RPG Active Pharma.
Importance 10.0 Sentiment 0.0
priv
Financial advisor to RPG Active Pharma.
Importance 10.0 Sentiment 0.0
priv
Financial due diligence partner to RPG Active Pharma.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.